Clinical Trials Logo

Filter by:
NCT ID: NCT05768464 Recruiting - Clinical trials for Non-clear Renal Cell Carcinoma

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

IUNU-RC
Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this prospective, multicenter, single-arm clinical study is to evaluate the efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant therapy for non-clear renal cell carcinoma with high-risk recurrence factors.

NCT ID: NCT05768399 Recruiting - Asthma in Children Clinical Trials

The Role of Biomarkers in the Occurrence and Development of Asthma

Start date: July 4, 2023
Phase:
Study type: Observational

To study the expression level of biomarkers such as GITRL in peripheral blood of children with asthma and analyze their correlation with the severity of asthma. To study the predictive value of biomarkers level for the occurrence and development of asthma. And to provide supplementary detection means and predictive indicators for the diagnosis of asthma and the severity of asthma.

NCT ID: NCT05768321 Recruiting - Clinical trials for Advanced Solid Tumors

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Start date: November 4, 2021
Phase: Phase 1
Study type: Interventional

The overall objective of this Phase 1 study is to evaluate the safety, Pharmacokinetics (PK), and anti-tumor activity of daily oral dosing with GEC255 tablets in subjects with advanced solid tumor with Kirsten Rat Sarcoma (KRAS) p.G12C mutation. To determine the recommended Phase 2 dose (RP2D) based on assessments of multiple dose escalation and expansion in target cohorts.

NCT ID: NCT05768230 Not yet recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV

Start date: March 22, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Acute respiratory distress syndrome (ARDS) is often complicated by right ventricular dysfunction (RVD), Acute cor pulmonale is the most serious form of ARDS complicated with RVD.Levosimendan is indicated for short-term treatment of acute decompensated heart failure that is not responding well to conventional therapy and requires increased myocardial contractile force.In 2016, the European Society of Cardiology issued recommendations for the management of acute right heart failure, stating that levosimendan can improve right ventriculo-pulmonary artery coupling by both increasing right heart contractility and reducing pulmonary vascular resistance.However, the clinical application of levosimendan in the treatment of ARDS right heart dysfunction is insufficient.Therefore, this study intends to use transesophageal ultrasound to evaluate right ventricular function, reduce the limitation of poor right ventricular window in transthoracic echocardiography, and conduct a multi-center randomized controlled study to further explore the effects of levosimendan on right ventricular function in ARDS patients, such as tricuspid ring systolic displacement (TAPSE) and tricuspid ring systolic displacement velocity (S '). Effects of right ventricular area change fraction (RV FAC), right ventricular end-diastolic area/left ventricular end-diastolic area (RVEDA/LVEDA), pulmonary circulation resistance (PVR), hemodynamics and mortality.

NCT ID: NCT05768204 Recruiting - Severe Pneumonia Clinical Trials

Research on the Treatment of Severe Community-acquired Pneumonia in Children

Start date: March 10, 2023
Phase: Phase 4
Study type: Interventional

The need for glucocorticoid therapy in children with severe community-acquired pneumonia in the acute phase of the disease remains unclear. The implementation of this study could provide strong evidence on the need for adjuvant glucose therapy in children with severe community-acquired pneumonia.

NCT ID: NCT05768152 Not yet recruiting - Eye Diseases Clinical Trials

Repeated Low-Level Red-Light Therapy Shortens Axial Length

Start date: March 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to investigate the incidence and magnitude of axial length shortening after repeated low-level red-light therapy in high myopia children and teenagers.

NCT ID: NCT05767931 Not yet recruiting - Clinical trials for Invasive Breast Cancer

Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer

Start date: March 6, 2023
Phase:
Study type: Observational

This is a prospective, single-center, non-randomized, non-controlled study

NCT ID: NCT05767892 Not yet recruiting - Clinical trials for Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Start date: May 1, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups YK-029A group or Platinum-based chemotherapy group. Participants will receive YK-029A orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.

NCT ID: NCT05767866 Recruiting - Treatment Clinical Trials

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Start date: March 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study aimed to evaluate the safety and preliminary efficacy of YK-029A, a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in treated or untreated patients with advanced non-small cell lung cancer (NSCLC).

NCT ID: NCT05767710 Recruiting - Sarcopenia Clinical Trials

A Study of the Telerehabiliation Intervention Effect of the Tai Chi Exercise on Elderly With Sarcopenia

Start date: April 10, 2023
Phase: N/A
Study type: Interventional

Sarcopenia is an age-related disease characterized by a progressive decrease in skeletal muscle content and loss of muscle function. Tai Chi exercises have been shown to improve skeletal muscle mass in elderly people suffering from sarcopenia. However, offline interventions are a very labor- and financial-intensive approach. Therefore, researchers designed an artificial intelligence-assisted program and Tai Chi exercise format to investigate whether a remote rehabilitation approach could replace face-to-face interventions